

# Sub-epidermal moisture assessment as an adjunct to visual assessment in the reduction of pressure ulcer incidence

**Objective:** To assess the effectiveness of sub-epidermal moisture (SEM) assessment technology as an adjunct to visual assessment to reduce pressure ulcer (PU) incidence alongside standard PU care pathways.

**Method:** Data were obtained from wards located within 28 institutions in the UK, Canada, Belgium, Spain and Ireland. At each ward, the proportion of patients scanned who were observed to have one or more PUs of Category 2 or above during a pre-Pressure Ulcer Reduction Programme (PURP) implementation period starting between November 2017 and July 2018 was recorded. The proportion of patients scanned who were observed to have one or more PUs of Category 2 or above during a post-PURP implementation period starting between November 2018 and July 2019 was also recorded. A meta-analysis was conducted on the data

using wards as the unit of analysis, to facilitate overall estimate of the PURP. A sensitivity study was also conducted to assess the sensitivity of results to data from specific institutions.

**Results:** A synthesised estimate of the overall relative risk (RR) was calculated to be 0.38 (95% confidence interval 0.26 to 0.56). Hence the risk of PU in the post-PURP cohort was about one-third that of the corresponding risk in the pre-PURP cohort. The sensitivity analysis revealed no evidence that any individual ward exerted excessive influence on the findings.

**Conclusion:** The analysis has revealed strong evidence that implementation of the PURP was associated with reduction in incidence of Category 2 or above PUs across a wide range of clinical settings.

**Declaration of interest:** The authors have no conflicts of interest to declare.

meta-analysis • pressure ulceration • pressure ulcer reduction programme • SEM scanner • sub-epidermal moisture • wound • wound care • wound healing

**P**ressure ulcers (PUs), defined as ‘a localised area of skin and soft-tissue damage that usually occurs over bony prominences, due to pressure or pressure in combination with shear’<sup>1</sup>, are a common type of hard-to-heal wound categorised in four stages, with an additional unstageable category and suspected deep tissue injury.<sup>2</sup>

A serious form of avoidable harm to patients, PUs have widespread universal financial impacts: in the period 2017–18, approximately 200,000 people in the UK developed a new PU, with a daily cost of £1.4 million.<sup>3</sup> Using data obtained from The Health Improvement Network (THIN) database, Guest et al.<sup>4</sup> estimated the costs of managing PUs in the UK as ranging from £1400 for a category 1 ulcer to in excess of £8500 for more severe types of PU. Attributable to their gravity and the clinical nursing time involved in patient care, daily treatment costs of managing PUs have been estimated at between £1214–14,108, depending on severity.<sup>5</sup> In the US, approximately 2.5 million patients suffer hospital-acquired PUs (HAPUs) at an annual cost of almost US\$26.8 billion.<sup>6</sup>

development of a PU, together with external forces such as pressure, shear and friction.<sup>7</sup> Heat and moisture in the environment<sup>8,9</sup> can increase their likelihood. Regular patient repositioning, the use of pressure-relieving devices, and frequent visual and physical skin inspections are strategies commonly used to avert pressure damage developing in at-risk patients. Identifying at-risk patients through the completion of risk assessment and identification tools, alongside a visual skin assessment to detect visible signs of tissue damage, are techniques used in clinical practice to maintain healthy skin integrity.<sup>10</sup> A limiting factor of such preventative methods is the reliance on individual clinical judgement to predict and assess the likelihood of emerging and potentially non-visible tissue damage. This subjective approach, which is open to individual interpretation, can expose patients to unnecessary risk if such assessments are inadequate.<sup>11,12</sup> As the physical signs of tissue damage are usually only visible on the surface of the skin 3–10 days after damage

## Pressure ulcer assessment and identification

Individual patient factors (such as patient comorbidities) and external factors in the environment that have a negative effect on skin integrity can induce the

**Karen Ousey**,<sup>1,2</sup> PhD, Professor of Skin Integrity, Director for the Institute of Skin Integrity and Infection Prevention; **John Stephenson**,<sup>1,2</sup> PhD, Senior Lecturer in Biomedical Statistics; **Joanna Blackburn**,<sup>1,2</sup> PhD, Research Fellow

\*Corresponding author email: J.Stephenson@hud.ac.uk

**1** School of Human & Health Sciences, University of Huddersfield, UK. **2** Institute of Skin Integrity and Infection Prevention, University of Huddersfield, UK.

has started to occur,<sup>13</sup> a patient's skin health can significantly deteriorate before an effective PU intervention is adopted.

Patient outcomes and wound healing trajectory are largely dependent on the clinician's ability to accurately identify damaged skin, and the literature describes the impact that this approach to PU treatment and management can have on patient experiences of care.<sup>14</sup> Physical changes in the skin as a result of pressure, including an increased inflammatory response, localised tissue oedema and an increase in sub-epidermal moisture (SEM),<sup>15</sup> mean that a dependence on visual assessment to detect pressure damage represents a missed opportunity to implement early interventions to prevent escalation. The National Institute for Health and Care Excellence (NICE) recommendations<sup>11</sup> for PU prevention and management highlight the importance of training and education for healthcare practitioners (HCPs) in undertaking a visual skin assessment and using appropriate PU prevention strategies. However, some HCPs continue to have difficulties making evidence-based decisions in the absence of objective tools to support the identification of microscopic tissue damage.<sup>16</sup>

### The Pressure Ulcer Reduction Programme

Recent advances in SEM assessment technology have been used to reduce PU incidence alongside standard PU care pathways as an adjunct to the current standard of care.<sup>17</sup> The Pressure Ulcer Reduction Programme (PURP) is a potential tool to reduce the incidence of pressure ulceration in hospital patients by enabling clinicians to collect data on the inclusion of SEM in clinical practice. PURP programmes are designed using a pragmatic framework to replicate routine clinical practice in daily PU care. The framework and implementation methodology aligns with NICE guidelines described in the Real World Evidence DSU Technical Support Document 17, 2016 and is compliant with the General Data Protection Regulation 2016/279.<sup>18</sup>

SEM uses biocapacitance to notify clinicians that a patient has an increased risk of developing a PU before such damage is visible on the skin.<sup>19</sup> Institution- and patient-level data demonstrate that SEM has the potential to prompt appropriate interventions with associated financial benefits. For example, Padula et al.<sup>6</sup> evaluated the cost-effectiveness of using SEM assessment technology in comparison to existing HAPU prevention guidelines using a Markov modelling technique and established that using the technology was associated with cost savings of US\$4054 per acute care admission. For every 1000 hospital admissions in high-risk acute care, the technology was found to have the potential to eliminate seven HAPU-related deaths and reduce patient length of hospital stay by approximately 206 days. Gefen<sup>20</sup> used probabilistic modelling to understand the financial implications of using SEM assessment in a PU prevention strategy for the early detection of a HAPU and subsequent application of early interventions.

Where there was a low incidence of PUs (1.6%) the expected cost saving per patient was found to be £15.23, with estimated total savings of £0.6 million per annum and £3.3 million for a high incidence. The authors concluded that the predictive models suggest significant cost reduction through early identification of PU and supportive clinical decision-making when using SEM assessment technology compared to standard care.

The evidence suggests that the PURP can reduce PU incidence in hospitalised at-risk patients by providing an objective measure of a patient's tissue health to drive real-time decision-making and appropriate interventions. Smith<sup>21</sup> found that when the SEM was used on the heels and sacrum of hospitalised patients considered at risk of developing a PU (Waterlow score >10) once a day from admission over a 2-month period, no patients developed a PU during their inpatient stay, despite recording a delta reading of  $\geq 0.6$  (indicative of the early signs of pressure damage), although one patient was found to have developed a PU within 7 days of discharge. In the UK, Littlefield and Kellett<sup>22</sup> found a 95% reduction in grade 2–4 HAPUs when using the PURP on 234 inpatients; Raine<sup>23</sup> found a 46.8% reduction in HAPUs when the PURP was used in a palliative care setting; and Ore et al.<sup>24</sup> also found a reduction in HAPUs in the community setting in a sample of 17 palliative care patients, with the majority of staff reporting that the tool had made a significant impact on their clinical decision-making. Okonkwo et al.<sup>19</sup> evaluated the sensitivity and specificity of the SEM when used by 'generalists' with no specific training in PU visual assessment, compared to 'specialists', using a blinded, longitudinal prospective design involving patients across 12 acute and post-acute hospital sites in the UK (three acute care settings; n=42) and USA (six acute care, three post-acute settings; n=147). The SEM Scanner (Bruin Biometrics, USA) was found to have a sensitivity of 87.5% in identifying PUs and the device produced a positive finding 4.74 days (standard deviation (SD): 2.39 days) earlier. Specificity was lower at 32.9% (95% confidence interval (CI) 28.3–37.8%), although achieving high sensitivity may be considered to be of greater priority. Hence the scanner can be considered to be a conservative diagnostic tool; although a certain fraction of false positive cases will be recorded, very few genuine cases will be missed.

In addition, Raizman et al.<sup>17</sup> undertook a two-phase clinical comparison of the SEM Scanner to evaluate the clinical utility of the device in patients at risk (using the Braden risk assessment tool) of developing HAPUs in Canada at one of the three hospitals. Patients (n=89) were assessed and scanned five times per week for 1 month or until discharge, receiving standard of care clinical risk assessment by trained nurses, but in only the second phase of the study were SEM readings used in clinical decision-making to determine appropriate interventions. Results showed a significant difference in the observed PU incidence between phases, with a 93% reduction in HAPU incidence when patient assessments

and care planning incorporated SEM delta values. More specifically, 12 out of 89 patients (13.5%) in phase 1 developed visible PUs, compared to 1.0% in phase 2, despite the phase 2 patients being more clinically unwell than the phase 1 patients.

There are obvious clinical benefits of using SEM scanning technology in clinical practice to reduce the incidence of PU in at-risk patients and the literature points to the positive impact that this approach has on clinical practice, nurse decision-making and the associated financial benefits.

The aim of this paper is to assess the effectiveness of the PURP in reduction of category 2 or above pressure ulceration by conducting a meta-analysis to compare incidence pre- and post-implementation in patients in a variety of settings across several countries in a multisite study. A subsidiary aim includes the investigation of differential effects across setting types.

### Ethical approval

The PURP was designed as a quality improvement process using a pragmatic framework, to be used in everyday PU care practice with minimal modifications to existing care pathways. The scanning device was used on-label and verbal consent was required before scanning patients. Owing to the non-invasive and non-significant-risk use of the device, and a quality improvement-focused study design, these implementation studies were not subject to institutional review board (IRB) oversight and ethics committee approvals.

### Methods

#### Data collection

Anonymised data were obtained from 28 institutions in the UK, Belgium, Canada, Spain and Ireland. The setting of each institution was categorised as category A or Category B. Category A settings included: elderly/long-term care, orthopaedic/trauma, rehabilitation/stroke/neurology, medium-to-long-term stay medical and community settings. Category B settings included: general medical, intensive care unit (ICU), mixed surgical, renal, vascular, orthopaedic/short stay trauma, diabetes and palliative settings. In each setting, the number of patients admitted (recorded admissions) and the number of patients with one or more PUs of category 2 or above during a pre-PURP implementation period starting between November 2017 and July 2018 was recorded. From this information, the proportion of patients reported with one or more PUs of category 2 or above during the implementation period was extracted. The duration of this period was not recorded for all institutions but was given as 12 months in all institutions in which the duration was recorded.

The proportion of patients scanned at the sacrum and heels who were observed to have one or more PUs of category 2 or above during a post-PURP implementation period starting between November 2018 and July 2019 was determined, again evaluated from recordings of the

**Table 1. Summary of featured institutions, setting and categorisation**

| Institution | Country | Pre-PURP setting                    | Category |
|-------------|---------|-------------------------------------|----------|
| Site 01     | UK      | Medical                             | B        |
| Site 02     | UK      | Elderly care                        | A        |
| Site 03     | UK      | Orthopaedic trauma                  | A        |
| Site 04     | UK      | Orthopaedic trauma                  | A        |
| Site 05     | Canada  | Medical                             | B        |
| Site 06     | UK      | ICU                                 | B        |
| Site 07     | Spain   | Elderly care                        | A        |
| Site 08     | UK      | Rehabilitation and stroke           | A        |
| Site 09     | UK      | Orthopaedic trauma                  | A        |
| Site 10     | UK      | Mixed surgical                      | B        |
| Site 11     | UK      | Renal                               | A        |
| Site 12     | Belgium | Vascular surgery                    | B        |
| Site 13     | Belgium | Rehabilitation                      | A        |
| Site 14     | Ireland | Orthopaedic                         | B        |
| Site 15     | Belgium | Elderly care                        | A        |
| Site 16     | Belgium | Elderly care                        | A        |
| Site 17     | Belgium | Elderly and long-term care          | A        |
| Site 18     | UK      | Trauma and orthopaedics             | A        |
| Site 19     | UK      | Stroke and neurology rehabilitation | A        |
| Site 20     | UK      | Medical                             | B        |
| Site 21     | UK      | Orthopaedic trauma                  | A        |
| Site 22     | Spain   | Trauma – short stay                 | B        |
| Site 23     | Spain   | ICU                                 | B        |
| Site 24     | Spain   | Medical – medium/long stay          | A        |
| Site 25     | Spain   | Medical – medium/long stay          | A        |
| Site 26     | UK      | Medical – diabetes specialty        | B        |
| Site 27     | UK      | Palliative setting                  | B        |
| Site 28     | UK      | Community setting                   | B        |

Category A: elderly/long-term care, orthopaedic/trauma, rehabilitation/stroke/neurology, medium-to-long-term stay medical and community settings  
 Category B: general medical, ICU, mixed surgical, renal, vascular, orthopaedic/short stay trauma, diabetes and palliative settings  
 ICU—intensive care unit; PURP—Pressure Ulcer Reduction Programme

number of patients scanned and the number of patients with one or more PUs of category 2 or above. This implementation period generally commenced within a few days of the end of the corresponding pre-PURP implementation period for that ward. The duration of this period was not recorded for all institutions but was given as between 2 weeks and 6 months in the institutions in which the duration was recorded.

### Statistical analysis

The sample was summarised descriptively by implementation period. Z-tests for the comparison of two proportions was conducted on each institution, comparing the proportion of patients who were observed to have one or more PUs of category 2 or above, pre- and post-PURP implementation. An analysis of covariance (ANCOVA) was conducted to

**Table 2. Comparison of pre- and post-PURP PU proportions of observed patients with PUs (individual institutions)**

| Site    | Pre-PURP                    |                  |                                | Post-PURP                   |                  |                                | Z-statistic | p-value |
|---------|-----------------------------|------------------|--------------------------------|-----------------------------|------------------|--------------------------------|-------------|---------|
|         | Category 2+ PU observations | Patients scanned | Proportion of patients with PU | Category 2+ PU observations | Patients scanned | Proportion of patients with PU |             |         |
| Site 01 | 23                          | 1642             | 1.40%                          | 0                           | 35               | 0.00%                          | 0.705       | 0.481   |
| Site 02 | 25                          | 495              | 5.05%                          | 2                           | 234              | 0.85%                          | 2.801       | 0.005*  |
| Site 03 | 10                          | 308              | 3.25%                          | 0                           | 99               | 0.00%                          | 1.815       | 0.069   |
| Site 04 | 16                          | 384              | 4.17%                          | 0                           | 34               | 0.00%                          | 1.214       | 0.225   |
| Site 05 | 12                          | 89               | 13.48%                         | 2                           | 195              | 1.03%                          | 4.498       | <0.001* |
| Site 06 | 1                           | 12               | 8.33%                          | 0                           | 12               | 0.00%                          | 1.022       | 0.307   |
| Site 07 | 3                           | 20               | 15.00%                         | 0                           | 20               | 0.00%                          | 1.801       | 0.072   |
| Site 08 | 13                          | 383              | 3.39%                          | 1                           | 40               | 2.50%                          | 0.301       | 0.764   |
| Site 09 | 27                          | 3089             | 0.87%                          | 0                           | 59               | 0.00%                          | 0.721       | 0.471   |
| Site 10 | 14                          | 1242             | 1.13%                          | 0                           | 64               | 0.00%                          | 0.854       | 0.393   |
| Site 11 | 21                          | 1120             | 1.88%                          | 0                           | 41               | 0.00%                          | 0.885       | 0.376   |
| Site 12 | 1                           | 868              | 0.12%                          | 0                           | 105              | 0.00%                          | 0.348       | 0.728   |
| Site 13 | 5                           | 795              | 0.63%                          | 0                           | 45               | 0.00%                          | 0.534       | 0.594   |
| Site 14 | 40                          | 328              | 12.20%                         | 0                           | 31               | 0.00%                          | 2.063       | 0.039*  |
| Site 15 | 29                          | 134              | 21.64%                         | 1                           | 34               | 2.94%                          | 2.543       | 0.011*  |
| Site 16 | 13                          | 37               | 35.14%                         | 1                           | 30               | 3.33%                          | 3.184       | 0.001*  |
| Site 17 | 2                           | 32               | 6.25%                          | 1                           | 22               | 4.55%                          | 0.269       | 0.788   |
| Site 18 | 5                           | 892              | 0.56%                          | 0                           | 194              | 0.00%                          | 1.045       | 0.296   |
| Site 19 | 9                           | 206              | 4.37%                          | 0                           | 155              | 0.00%                          | 2.635       | 0.008*  |
| Site 20 | 12                          | 1123             | 1.07%                          | 0                           | 212              | 0.00%                          | 1.512       | 0.131   |
| Site 21 | 16                          | 625              | 2.56%                          | 2                           | 136              | 1.47%                          | 0.758       | 0.449   |
| Site 22 | 20                          | 1235             | 1.62%                          | 0                           | 26               | 0.00%                          | 0.654       | 0.513   |
| Site 23 | 4                           | 657              | 0.61%                          | 0                           | 23               | 0.00%                          | 0.375       | 0.707   |
| Site 24 | 55                          | 1490             | 3.69%                          | 0                           | 25               | 0.00%                          | 0.979       | 0.328   |
| Site 25 | 70                          | 627              | 11.16%                         | 0                           | 20               | 0.00%                          | 1.582       | 0.114   |
| Site 26 | 14                          | 838              | 1.67%                          | 0                           | 61               | 0.00%                          | 1.017       | 0.309   |
| Site 27 | 34                          | 377              | 9.02%                          | 7                           | 146              | 4.79%                          | 1.612       | 0.107   |
| Site 28 | 37                          | 230              | 16.09%                         | 2                           | 17               | 11.76%                         | 0.472       | 0.637   |

\*Statistically significant at the 5% significance level; PU—pressure ulcer; PURP—Pressure Ulcer Reduction Programme

assess the relationship between the outcome PU incidence (post-PURP implementation) and institution category, controlling for PU incidence (pre-PURP implementation).

A random effects meta-analysis, using the DerSimonian and Laird method, was conducted on the data to obtain an overall estimate of the effect of the PURP, comparing the relative risk (RR) of PU incidence at each included institution individually pre- and post-PURP implementation. RR was calculated as:

$$RR = \frac{\text{Incidence of PU (post-PURP)}}{\text{Incidence of PU (pre-PURP)}}$$

with a correction factor of 0.5 applied in cases of zero events, following common practice.

A sensitivity analysis was conducted by omitting each included study in turn and using a meta-analysis

to estimate the effect of interest from the remaining studies. These estimates with their confidence intervals were plotted on an influence plot. Excessive influence of any individual study may be indicated by the point estimate of its omitted analysis lying outside the CI of the combined analysis; or if its omitted meta-analysis estimate differs in significance relative to the estimate of the combined analysis.

The assessment of small-study (i.e., ward) effects was facilitated using a funnel plot (a scatterplot of measures of study precision against study-specific effect sizes).

A L'Abbé plot of the PU incidence post-PURP implementation against PU incidence pre-PURP implementation was also constructed, which illustrates variation in observed results as an aid to exploring the heterogeneity of effect estimates.

All analyses were conducted using Stata Statistical Software, version 14.0 I/C (StataCorp, US).


**Results**

The institutions featured, their settings and classifications, are summarised in Table 1.

The proportion of patients who were observed to have one or more PUs of category 2 or above pre- and post-PURP implementation is summarised in Table 2, including Z-statistics and p-values. Pre-post differences which were statistically significant at the 5% significance level are starred.


Pre-PURP implementation, the proportion of patients who were observed to have one or more PUs of category 2 or above ranged from 35.1–0.12%. Post-PURP implementation, the proportion of patients scanned who were observed to have a PU of category 2 or above ranged from 11.8–0.00% (19 institutions). All 28 institutions observed a reduction in proportion of observed PUs between the two implementation periods, with statistically significant reductions (at the 5% significance level) in six institutions according to the Z-test. Institution category was not significantly associated with PU incidence, post-PURP implementation ( $F_{1,25}=0.571$ ;  $p=0.457$ ) and had an effect of low magnitude (partial- $\eta^2=0.022$ ) according to the ANCOVA procedure. The parameter estimate for institution category of 0.007 (95% CI: -0.012–0.026)

**Fig 1.** Overall proportions of patients with pressure ulceration pre- and post-pressure ulcer reduction programme (PURP) (with associated 95% confidence intervals (CIs))




indicated that at best estimate, PU incidence, post-PURP implementation, was 0.7% higher in category A


**Fig 2.** Forest plot for relative risk of pressure ulcer (PU) incidence pre- and post-pressure ulcer reduction programme (PURP) implementation



**Fig 3.** Sensitivity analysis influence plot for pressure ulcer incidence pre- and post-pressure ulcer reduction programme implementation CI—confidence interval



**Fig 4.** Funnel plot for pressure ulcer incidence pre- and post-pressure ulcer reduction programme implementation



institutions than in category B institutions. However, this is a non-significant effect.

The pooled overall proportions of patients with pressure ulceration pre- and post-PURP (with associated 95% CIs) is summarised graphically in Fig 1; revealing no overlap between the two sets of CIs. This is indicative of a significant difference in proportions pre- and post-PURP ( $p < 0.01$ ).

The meta-analysis revealed that a synthesised estimate of the overall RR was calculated to be 0.38 (95% CI:

0.26–0.56). Hence the risk of PU in the post-PURP cohort was about one-third that of the corresponding risk in the pre-PURP cohort, notwithstanding the effects of the correction factor. A Z-test of the RR revealed strong evidence to reject the hypothesis that the risk of PU was equal in the two groups ( $Z = 6.33$ ;  $p < 0.001$ ).

The meta-analysis also determined that there was no evidence for heterogeneity between studies according to Cochran's test:  $X^2_{(27)} = 21.95$ ;  $p = 0.740$ . The  $I^2$  statistic (variation in RR attributable to heterogeneity) was approximately 0.0%; indicating negligible statistical heterogeneity.

The data are summarised in a forest plot (Fig 2) in which the homogeneity of effects is apparent. All cases in which the relative risk appears to have increased post-PURP are artefacts, caused by the correction factor applied to the cases of zero post-PURP incidence.

The sensitivity analysis revealed no evidence that any individual ward exerted excessive influence on the findings; with all point estimates of omitted analysis lying outside the confidence interval of the combined analysis; and no differences of significance between the estimates of the omitted analysis and combined analyses (Fig 3).

The funnel plot (Fig 4) revealed some limited evidence for small-study (i.e., ward) effects, with moderate departure from the symmetrical (inverted) funnel shape indicative of absence of effects.

The L'Abbé plot (Fig 5) illustrates the scale of the preponderance of studies with higher levels of PU incidence pre-PURP; and the relative heterogeneity of data, with most results clustered within narrow limits. Points falling below the line of equality indicate wards with higher levels of PU incidence pre-PURP. While points falling above the line of equality would normally indicate wards with higher levels of PU incidence post-PURP, all are in fact data artefacts arising from the necessity to apply a correction factor to zero-event cases.

### Discussion

There was universal reduction in PU incidence from the pre-PURP to post-PURP implementation periods across all departments and settings, with no evidence for a differential effect across different categories of settings. In many individual settings, post-PURP incidences drop to zero. This may have been a result of practitioners being increasingly aware of potential skin damage and implementing effective preventative strategies in a timely manner. However, Raizman et al.<sup>17</sup> concluded that there was no evidence for the Hawthorne effect (a change in outcomes due to a change in behaviour of participants as a result of observation of their involvement in a study) associated with usage of the SEM Scanner. Raizman et al.<sup>17</sup> conducted a two-phase study with patients provided with standard care for risk assessment and scanned in both phases, but scanner readings were used to determine interventions in the second phase only; PU

incidence decreased only when the scanner was used to influence clinical interventions.


Despite this, not all reductions are significant at the 5% significance level as measured in individual settings. This is likely to be the result of underlying low pre-PURP incidences, leaving limited scope for improvement in the post-PURP implementation phase; and small sample sizes in some institutions, particularly in the post-PURP implementation phase. Additionally, the pre-PURP implementation periods and post-PURP implementation time periods and the number of patients admitted, or scanned, during these phases were not similar in multiple settings, which may have contributed to the lack of statistical significance at the 5% level as measured in these settings.

While the current analysis was conducted at the patient level, research by Jayabal et al.<sup>25</sup> has revealed differences in SEM values across different anatomical sites in a healthy cohort of participants. Hence consideration of both site-specific and individual demographic factors may be required in the assessment of the utility of the SEM Scanner as a predictive tool, which will be addressed in a future analysis.

The meta-analysis reveals the risk of PU incidence post-PURP implementation to be approximately one-third the risk of PU incidence pre-PURP implementation; i.e., an approximately threefold decrease in PURP incidence. Because of the correction factor applied to a substantial fraction of the wards included in the analysis, which had zero post-PURP incidences, this figure may be a considerable underestimate. No single ward or setting excessively influenced the findings of this analysis, with high levels of homogeneity inferred from the forest plot and L'Abbé plot. In general, precision of estimated intervention effects increased with setting size, with effect estimates from small studies scattering more widely at the bottom of the funnel plot (Fig 3), albeit with some departure from expectations in terms of the shape of the data.

There has been discussion in the literature regarding effectiveness of pressure ulcer risk assessment tools and their effectiveness in prevention of skin damage,<sup>26-28</sup> the authors concluding that there was no randomised clinical trial evidence suggesting that conducting a structured risk assessment made any difference to pressure ulcer incidence. Hence options for reducing skin damage and PU incidence are limited, and in this context, the current analysis revealed the value of the PURP with the conclusion that there is strong evidence to suggest that incorporating the PURP into clinical practice for the early identification of category 2 or above pressure ulcers has the potential to reduce the PU incidence. Budri et al.<sup>29</sup> drew attention to movement values for an older person, highlighting that the median number of movements per hour of the older person was almost half the median number of movements per hour performed by younger adults. The authors suggested that in immobile patients,

**Fig 5.** L'Abbé plot for pressure ulcer incidence pre- and post-pressure ulcer reduction programme (PURP) implementation



pressure-related forces over bony prominences may link to tissue damage by pressing tissue layers down and causing occlusion of lymphatic and blood vessels. However, they warned that attention must be paid to those who can move as they may not necessarily move into a good position. They concluded that PUs occurred both in low and high movers, and the addition of a more objective skin assessment enabled greater detection of impending tissue damage.

#### Limitations of study

There were a wide range of clinical areas used to collect the data. However, data were collected by a range of clinicians, and therefore it is difficult to ensure there was consistency across grading of ulcers. Future studies should ensure data collection is from a research team, ensuring inter-rater reliability.

#### Conclusion

The PURP programme has been shown to produce positive patient outcomes and associated cost benefits through limiting the number of patients who may potentially go on to develop severe and enduring hard-to-heal wounds. Incorporating such an approach for the strategic management of PU has the potential to enable clinicians to identify developing tissue damage before it is visible on the patient's skin and employ appropriate early interventions to limit the devastating

## Reflective questions

- How can implementation of a reduction programme reduce incidence of category 2 and above pressure ulcers (PUs)?
- How can a sub-epidermal moisture (SEM) scanner be effectively used as an adjunct to visual assessment to reduce PU incidence alongside standard PU care pathways?
- Are there any differential effects across ward types in the effectiveness of the programme? If so why?

## References

- 1 National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and treatment of pressure ulcers: clinical practice guideline. Cambridge Media, 2014. <https://npiap.com/page/Guidelines>
- 2 European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and treatment of pressure ulcers/injuries: quick reference guide. Emily Haesler (ed). EPUAP/NPIAP/PPPIA; 2019
- 3 Guest JF, Vowden K, Vowden P. The health economic burden that acute and chronic wounds impose on an average clinical commissioning group/health board in the UK. *J Wound Care* 2017; 26(6):292–303. <https://doi.org/10.12968/jowc.2017.26.6.292>
- 4 Guest JF, Fuller GW, Vowden P, Vowden KR. Cohort study evaluating pressure ulcer management in clinical practice in the UK following initial presentation in the community: costs and outcomes. *BMJ Open* 2018; 8(7):e021769. <https://doi.org/10.1136/bmjopen-2018-021769>
- 5 Bennett G, Dealey C, Posnett J. The cost of pressure ulcers in the UK. *Age Ageing* 2004; 33(3):230–235. <https://doi.org/10.1093/ageing/afh086>
- 6 Padula WV, Malaviya S, Hu E et al. The cost-effectiveness of sub-epidermal moisture scanning to assess pressure injury risk in U.S. health systems. *Journal of Patient Safety and Risk Management* 2020; 25(4):147–155. <https://doi.org/10.1177/2516043520914215>
- 7 García-Fernández FP, Agreda JJ, Verdú J, Pancorbo-Hidalgo PL. A new theoretical model for the development of pressure ulcers and other dependence-related lesions. *J Nurs Scholarsh* 2014; 46(1):28–38. <https://doi.org/10.1111/jnu.12051>
- 8 van Marum RJ, Meijer JH, Ribbe MW. The relationship between pressure ulcers and skin blood flow response after a local cold provocation. *Arch Phys Med Rehabil* 2002; 83(1):40–43. <https://doi.org/10.1053/apmr.2002.26827>
- 9 Jan YK, Brienza D. Technology for pressure ulcer prevention. *Top Spinal Cord Inj Rehabil* 2006; 11(4):30–41. <https://doi.org/10.1310/26R8-UNHJ-DXJ5-XG7W>
- 10 National Institute for Health and Care Excellence. Pressure ulcers prevention and management: clinical guideline [CG179]. 2014. <https://tinyurl.com/2p882dna> (accessed 13 April 2021)
- 11 Moore ZE, Patton D. Risk assessment tools for the prevention of pressure ulcers. *Cochrane Database Syst Rev* 2019; 2019(1):CD006471. <https://doi.org/10.1002/14651858.CD006471.pub4>
- 12 Bosanquet DC, Harding KG. Wound duration and healing rates: cause or effect? *Wound Repair Regen* 2014; 22(2):143–150. <https://doi.org/10.1111/wrr.12149>
- 13 Moore Z, Patton D, Rhodes SL, O'Connor T. Subepidermal moisture (SEM) and bioimpedance: a literature review of a novel method for early detection of pressure-induced tissue damage (pressure ulcers). *Int Wound J* 2017; 14(2):331–337. <https://doi.org/10.1111/iwj.12604>
- 14 Dowsett C. T.J.M.E. to improve patient outcomes: use of a clinical decision support tool to optimise wound care. *Br J Community Nurs* 2019; 24(Sup3):S6–S11. <https://doi.org/10.12968/bjcn.2019.24.Sup3.S6>
- 15 Peko Cohen L, Gefen A. Phantom testing of the sensitivity and precision of a sub-epidermal moisture scanner. *Int Wound J* 2019; 16(4):979–988. <https://doi.org/10.1111/iwj.13132>
- 16 Blackburn J, Ousey K, Stephenson J. Nurses' education, confidence, and competence in appropriate dressing choice. *Adv Skin Wound Care* 2019; 32(10):470–476. <https://doi.org/10.1097/01.ASW.0000577132.81124.88>
- 17 Raizman R, MacNeil M, Rapp L. Utility of a sensor-based technology to assist in the prevention of pressure ulcers: A clinical comparison. *Int Wound J* 2018; 15(6):1033–1044. <https://doi.org/10.1111/iwj.12974>
- 18 Bell H, Wailoo A, Hernandez Alava M et al. The use of real world data for the estimation of treatment effects in NICE decision making. Report by the Decision Support Unit: 2016. <https://tinyurl.com/2p86cc6s>
- 19 Okonkwo H, Bryant R, Milne J et al. A blinded clinical study using a subepidermal moisture biocapacitance measurement device for early detection of pressure injuries. *Wound Repair Regen* 2020; 28(3):364–374. <https://doi.org/10.1111/wrr.12790>
- 20 Gefen A, Kolsi J, King T et al. Modelling the cost-benefits arising from technology-aided early detection of pressure ulcers. *Wounds International* 2020; 11(1):22–29
- 21 Smith G. Improved clinical outcomes in pressure ulcer prevention using the SEM scanner. *J Wound Care* 2019; 28(5):278–282. <https://doi.org/10.12968/jowc.2019.28.5.278>
- 22 Littlefield S, Kellett N. Chasing zero results from a new pressure ulcer prevention bundle. Wounds UK Annual Conference 2016, Harrogate, UK, November 14–16, 2016. Poster 195. <https://epostersonline.com/wounds2016/node/464> (accessed 9 February 2022)
- 23 Raine G. Achieving a reduction of hospice acquired pressure damage in the palliative care setting. EWMA, Virtual Conference 2020
- 24 Ore N, Carver T. Implementing a new approach to pressure ulcer prevention. *J Community Nurs* 2020; 34(4):52–57
- 25 Jayabal H, Bates-Jensen BM, Abiakam NS et al. Anatomical variability of sub-epidermal moisture and its clinical implications. *J Tissue Viability* 2021; 30(3):434–438. <https://doi.org/10.1016/j.jtv.2021.04.003>
- 26 Moore ZE, Cowman S. Risk assessment tools for the prevention of pressure ulcers. *Cochrane Database Syst Rev* 2008; 2008(3):CD006471. <https://doi.org/10.1002/14651858.CD006471.pub2>
- 27 Moore ZE, Cowman S. Risk assessment tools for the prevention of pressure ulcers. *Cochrane Database Syst Rev* 2014; 2014(2):CD006471. <https://doi.org/10.1002/14651858.CD006471.pub3>
- 28 Moore ZE, Patton D. Risk assessment tools for the prevention of pressure ulcers. *Cochrane Database Syst Rev* 2019; 2019(1):CD006471. <https://doi.org/10.1002/14651858.CD006471.pub4>
- 29 Budri AM, Moore Z, Patton D et al. Sub-epidermal moisture measurement: an evidence-based approach to the assessment for early evidence of pressure ulcer presence. *Int Wound J* 2020; 17(6):1615–1623. <https://doi.org/10.1111/iwj.13437>

effects that PU can cause to patients in their care. Future research should focus on adopting the PURP into clinical practice for the treatment and management of PUs in different clinical settings. **JWC**

## Acknowledgements

The data for this analysis were made available by BBI Europe Ltd., Nether Alderley, UK